PDS Biotechnology Corporation

DB:EU6 Stock Report

Market Cap: €46.6m

PDS Biotechnology Valuation

Is EU6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of EU6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: EU6 (€0.8) is trading below our estimate of future cash flow value (€169.59)

Significantly Below Future Cash Flow Value: EU6 is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EU6?

Key metric: As EU6 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for EU6. This is calculated by dividing EU6's market cap by their current book value.
What is EU6's PB Ratio?
PB Ratio5.5x
BookUS$9.25m
Market CapUS$53.58m

Price to Book Ratio vs Peers

How does EU6's PB Ratio compare to its peers?

The above table shows the PB ratio for EU6 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.9x
2INV 2invest
0.5xn/a€45.6m
8V8 Genetic Analysis
1.3xn/a€43.5m
2INV 2invest
0.7xn/a€62.9m
7V0 Darwin
1x64.28%€95.4m
EU6 PDS Biotechnology
5.5x44.91%€53.6m

Price-To-Book vs Peers: EU6 is expensive based on its Price-To-Book Ratio (5.5x) compared to the peer average (0.9x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does EU6's PB Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
MDG1 Medigene
0.1x14.15%US$2.07m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
EU6 5.5xIndustry Avg. 2.9xNo. of Companies6PB00.61.21.82.43+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: EU6 is expensive based on its Price-To-Book Ratio (5.5x) compared to the European Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is EU6's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EU6 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate EU6's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EU6 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.80
€6.43
+699.35%
71.18%€12.85€2.57n/a3
Jun ’27€1.02
€6.43
+530.07%
71.18%€12.85€2.57n/a3
May ’27€0.84
€6.35
+654.72%
71.18%€12.71€2.54n/a3
Apr ’27€0.51
€7.79
+1,413.47%
66.67%€12.98€2.60n/a2
Mar ’27€0.58
€7.63
+1,206.19%
66.67%€12.72€2.54n/a2
Feb ’27€0.73
€6.44
+786.98%
71.18%€12.88€2.58n/a3
Jan ’27€0.68
€6.49
+859.58%
71.18%€12.97€2.59n/a3
Dec ’26€0.65
€6.49
+895.66%
71.18%€12.97€2.59n/a3
Nov ’26€0.81
€6.44
+695.06%
51.93%€11.17€3.87n/a3
Oct ’26€0.85
€6.44
+657.23%
51.93%€11.17€3.87n/a3
Sep ’26€1.03
€6.44
+525.19%
51.93%€11.16€3.86n/a3
Aug ’26€0.91
€6.41
+603.04%
51.93%€11.11€3.85n/a3
Jul ’26€1.14
€6.36
+457.05%
51.93%€11.03€3.82n/a3
Jun ’26€1.22
€6.67
+448.75%
51.93%€11.57€4.00€1.023
May ’26€1.10
€6.51
+490.41%
51.93%€11.29€3.91€0.843
Apr ’26€1.09
€7.51
+589.88%
38.03%€12.01€4.16€0.514
Mar ’26€1.29
€9.66
+647.89%
63.28%€20.03€4.29€0.584
Feb ’26€1.60
€11.10
+595.26%
55.27%€20.26€4.34€0.735
Jan ’26€1.63
€11.10
+582.85%
55.27%€20.26€4.34€0.685
Dec ’25€1.98
€10.96
+452.28%
55.27%€20.01€4.29€0.655
Nov ’25€2.83
€11.24
+297.00%
44.93%€19.04€6.35€0.815
Oct ’25€3.38
€11.15
+229.35%
44.93%€18.87€6.29€0.855
Sep ’25€2.81
€11.15
+297.19%
44.93%€18.87€6.29€1.035
Aug ’25€3.27
€11.17
+241.20%
50.00%€19.55€4.65€0.915
Jul ’25€2.67
€11.17
+318.38%
50.00%€19.55€4.65€1.145
Jun ’25€2.68
€11.96
+345.98%
44.85%€19.32€4.60€1.225
€6.63
Fair Value
87.9% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/17 06:23
End of Day Share Price 2026/06/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PDS Biotechnology Corporation is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Mayank MamtaniB. Riley Securities, Inc.
Kalpit PatelB. Riley Securities, Inc.